Icure Pharmaceutical Incorporation Logo

Icure Pharmaceutical Incorporation

A biopharmaceutical firm specializing in Transdermal Drug Delivery System technology.

175250 | KO

Overview

Corporate Details

ISIN(s):
KR7175250000
LEI:
Country:
South Korea
Address:
서울특별시 강남구 봉은사로104길 10 7층, 강남구

Description

Icure Pharmaceutical Incorporation is a biopharmaceutical company that researches, develops, manufactures, and commercializes high-tech drug products. The company's core expertise lies in its Transdermal Drug Delivery System (TDDS) technology, which facilitates 'Cure & Care' solutions through the skin. Its portfolio includes both pharmaceutical products, such as NSAIDS patches, and cosmetic lines developed with a pharmaceutical and medical foundation. Icure focuses on creating innovative formulations and drug delivery systems to improve therapeutic outcomes and patient convenience.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-01-10 00:00
주식등의대량보유상황보고서(약식)
Korean 59.8 KB
2025-01-02 00:00
주식등의대량보유상황보고서(일반)
Korean 99.4 KB
2024-12-27 00:00
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Korean 27.1 KB
2024-12-27 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2024-12-26 00:00
주요사항보고서(전환사채권발행결정)
Korean 71.4 KB
2024-12-26 00:00
최대주주변경을수반하는주식담보제공계약체결
Korean 22.8 KB
2024-12-11 00:00
주식등의대량보유상황보고서(일반)
Korean 99.5 KB
2024-11-29 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.3 KB
2024-11-14 00:00
분기보고서 (2024.09)
Korean 1.8 MB
2024-11-11 00:00
주식등의대량보유상황보고서(일반)
Korean 99.5 KB
2024-10-28 00:00
주식등의대량보유상황보고서(일반)
Korean 99.5 KB
2024-10-22 00:00
수시공시의무관련사항(공정공시) (도네페질 패치의 라이센스 및 제품 공급 계약)
Korean 9.3 KB
2024-09-25 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 52.5 KB
2024-09-23 00:00
주식등의대량보유상황보고서(약식)
Korean 64.1 KB
2024-09-11 00:00
전환가액의조정
Korean 10.6 KB

Automate Your Workflow. Get a real-time feed of all Icure Pharmaceutical Incorporation filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Icure Pharmaceutical Incorporation

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Icure Pharmaceutical Incorporation via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.